Beyond Weight Loss: Wegovy’s Broader Metabolic and Cognitive Benefits

10 October, 2025  |  Holy Winter - Healthcare Writer

Is Wegovy more than just a weight loss treatment? While primarily marketed for wqeight loss, Wegovy has benefits that go far beyond that.

Let’s explore some of its key health advantages.

Wegovy May Help to Protect Your Heart

Carrying excess weight can increase the risk of developing heart problems and related cardiovascular conditions.

Wegovy can help lower such risks.

In a large clinical trial, people with a BMI over 27kg/m2 - with existing heart disease (but no diabetes) - were given either Wegovy 2.4mg once a week (along with a control group who were administered a placebo) over a period of 2 years with impressive results!

• Those on Wegovy lost an average 9.4% of their body weight compared to that of just 0.88% in the placebo group.
• Also, the Wegovy group had 20% lower risk of major cardiovascular events, such as heart attacks and strokes.

Wegovy may also indirectly help people with existing heart conditions

Wegovy has been shown to help people who have certain types of heart failure with preserved ejection fraction (HFpEF). Research suggests that a significant proportion of HFpEF patients are obese, so Wegovy can contribute to weight loss, which can indirectly lead to a better quality of life for those who suffer from HFpEF.

In another study by Novo Nordisk, 529 patients were randomly treated with a weekly semaglutide injection once or a placebo for a year, and here are the findings:

• Those on Wegovy lost 15.2% of body weight, whilst placebo lost only 2.6% in comparison.
• The patients who were administered Wegovy also reported increased bodily movement functionality, as well as a general feeling better about themselves. On average, patients in the Wegovy group were able to walk 21.5 meters more in a 6-minute test than those in the placebo group, who only extended their travel distance by an average of 1 meter.

Can Wegovy Help with Kidney Health?

A large study called the FLOW trial looked at how semaglutide (Wegovy being a branded variety) can affect people with type 2 diabetes and chronic kidney disease.

Whilst research is still ongoing, here is what we know so far:

• Those who took semaglutide had a 24% lower risk of major kidney problems, such as kidney failure or requiring dialysis.
• In people with type 2 diabetes, it may help slow down kidney damage, meaning kidneys stay healthier for longer.
• Reducing protein in urine so your kidneys are under less stress.

How Wegovy Can Support People with PCOS Beyond Weight Loss

Those who suffer from PCOS (Polycystic Ovary Syndrome) may also suffer from weight gain, irregular periods, acne, and/or extra hair growth as a result of the condition: this is caused by an increased insulin resistance, which makes it more difficult for your body to use sugar optimally. Wegovy can help! Taking Wegovy can make your periods more regular, lower insulin resistance, reduce acne and prevent excessive hair growth.In most meta analysis studies, about 80% of people who lost 5% of their body weight using Wegovy also showed better insulin control!

Can Wegovy Help Brain Health and Function?

Semaglutide (Wegovy) has been shown to

• Help improve blood sugar control
• Reduce inflammation - as a result of weight loss
• Improve insulin resistance

Of which, the above are also indirectly linked to improved body positivity, mental health, clarity, and cognitive function. Ongoing research is also looking at how semaglutide might support memory, focu,s and overall better brain health, which will be useful in managing conditions such as Alzheimer's Disease. Ethical animal studies have suggested cursory observations that semaglutide can, in some cases, improve memory, reduce brain inflammation and protect brain cells. Research has found that mice with Alzheimer's-like symptoms even demonstrated better learning and thinking after treatment. Whilst such research is in the early stages, it’s an exciting area to watch.

How can pharmacists help you?

Pharmacists are trusted and regulated healthcare professionals who help patients make sense of medical developments. Whether its:

• considering Wegovy or similar weight loss injections
• managing side effects of Wegovy or similar weight loss medication

Your iQ Doctor pharmacist is here to guide you on every step of the way, answer any nagging questions and support your journey from prescriptions to progress.

iQ Doctor is a registered UK pharmacy that specialises in medical remedies for weight loss, erectile dysfunction, hair loss support and much more. Whether you require over-the-counter relief, or prescription-only medication, the experts at iQ Doctor can assist. Please get in touch if you need any further advice.

Also, be sure to keep in touch with iQ Doctor via our social media channels as well as keeping up to date with us by signing up to the mailing list.

References:

Lincoff, A. M., Brown‑Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt‑Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W. & Ryan, D. H.; SELECT Trial Investigators (2023) ‘Semaglutide and cardiovascular outcomes in obesity without diabetes’, New England Journal of Medicine, 389(24), pp. 2221–2232. doi: 10.1056/NEJMoa2307563. PMID: 37952131.

Kosiborod, M. N., Verma, S., Borlaug, B. A., Butler, J., Davies, M. J., Jensen, J., Rasmussen, S., Marstrand, P. E., Petrie, M. C., Shah, S. J., Ito, H., Schou, M., Melenovský, V., Abhayaratna, W. & Kitzman, D. et al. (2024) ‘Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP‑HFpEF trial’, Circulation, 149(3), pp. 204–216. doi:10.1161/CIRCULATIONAHA.123.067505. PMID: 37952180.

Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F., Bakris, G., Baeres, F. M., Idorn, T., Bosch‑Traberg, H., Lausvig, N. L. & Pratley, R. (2024) ‘Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes’, New England Journal of Medicine, 391(2), pp. 109–121. doi:10.1056/NEJMoa2403347.

Carmina, E. & Longo, R. A. (2023) ‘Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients. Available at: Unresponsive to Lifestyle Programs’, Journal of Clinical Medicine, 12(18), article 5921. doi:10.3390/jcm12185921.

British Heart Foundation. (2023). 'Wegovy' weight loss drug could improve heart failure symptoms. British Heart Foundation. Available at: https://www.bhf.org.uk/what-we-do/news-from-the-bhf/news-archive/2023/august/wegovy-weight-loss-drug-has-benefits-for-people-with-heart-failure-and-obesity

Zhang, Y., 2024. Semaglutide ameliorates Alzheimer's disease and restores cognitive function in pre-clinical models. La Presse Médicale, 53(1), pp.101–108. Available at: https://doi.org/10.1016/j.lpm.2023.11.004